Director Activity at Ionis Pharmaceuticals Signals Mixed Signals Amid Clinical and Financial Updates
A recent Form 4 filing disclosed that director Spencer R. Berthelsen sold $605,360 worth of IONIS PHARMACEUTICALS common stock on June 1, 2026, through a pre-arranged Rule 10b5-1 trading plan. Concurrently, he acquired shares by exercising non-qualified options. These transactions occurred against a backdrop of positive clinical developments for Io…